Beyond the Abstract - Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy, by Guru Sonpavde, MD
BERKELEY, CA (UroToday.com) - This was an open label, phase II trial of sunitinib for patients with progressive metastatic CRPC (castration resistant prostate cancer) following prior docetaxel chemotherapy and was conducted at 10 community cancer centers in the US Oncology Network.
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2009 UroToday ® All Rights Reserved |
